RenovoRx, Inc. Income Statement
RNXT|2 years of annual SEC 10-K data (FY2024-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 2 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Revenue
$43,000
FY2025
Gross Profit
$43,000
100.0% gross margin
Operating Income
-$11M
FY2025
Net Income
-$9M
FY2025
RenovoRx, Inc. reported $43,000 in revenue and $9M in net loss for FY2025. Revenue increased 0.0% from FY2024 to FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Piotroski F-Score: 1/9 criteria passed
- Currently unprofitable: Net income is negative
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 |
|---|---|---|
| Revenue | $43.0K | $43.0K |
| Cost of Revenue | $0 | - |
| Gross Profit | $43.0K | $43.0K |
| SG&A Expense | $5.0M | $5.7M |
| R&D Expense | $6.0M | $5.7M |
| Operating Income | -$11.0M | -$11.4M |
| Income Tax | $2.0K | - |
| Net Income | -$8.8M | -$10.2M |
| EPS (Basic) | -$0.40 | -$0.99 |
| EPS (Diluted) | -$0.40 | -$0.99 |
| Shares Outstanding | 24.0M | 10.7M |
| Gross Margin | 100.0% | 100.0% |
| Operating Margin | -25511.6% | -26502.3% |
| Profit Margin | -20497.7% | -23795.3% |